Ralph Snyderman, MD

Adjunct Professor of Medicine
James B. Duke Professor of Medicine
Chancellor Emeritus of Duke University
Campus mail 2424 Erwin Road, Suite 1101, Durham, NC 27705
Phone (919) 684-6637
Email address ralph.snyderman@duke.edu

Phagocytic leukocytes including neutrophils and macrophages play a critical role in immunologically mediated host defense and tissue destruction. These cells migrate to and become activated at sites of inflammation in response to chemoattractant factors, including -C5a, interleukin 8 (IL-8), formylated peptides (e.g. fMLP) Leukotriene B4(LTB4) and platelet activating factor (PAF). The responses of leukocytes to chemoattractants is mediated by G protein coupled receptors. The focus of this laboratory has been to define the mechanisms which regulate chemoattractant receptors activation, desensitization and priming. To study the mechanisms of leukocyte activation, we have developed genetic and biochemical techniques. We constructed epitope-tagged human formylpeptide, C5a, PAF, LTB4 and IL-8 receptor cDNAs and expressed receptors either singly or multiply in a cell line which mimics responses of human inflammatory cells. These RBL-2H3 cells are a basophilic cell line which endogenously contains thrombin receptors. Using this model system, we are studying desensitization, cross-desensitization and priming, a phenomenon whereby one stimulus leads to greatly enhanced responsiveness to a second stimulus. Our data have demonstrated an unexpected and interesting complexity in chemoattractant receptor phosphorylation and desensitization. We have defined kinases involved in receptor desensitization. Furthermore, we have identified motifs in the cytoplasmic tails of IL-8 and PAF receptors that appear to be critical for cell activation by their respective ligands. We have also identified a new form of chemoattractant receptor desensitization, termed class desensitization. A major effort of this laboratory is directed at defining the precise molecular events controlling leukocyte activation.

Clinical trials: None
Areas of expertise and national recognition: Immunology, Inflammation, Rheumatology and Medical Center Adminstration.

Education and Training

  • M.D., State University of New York at Brooklyn, 2000

Publications

Snyderman, R. "Personalized health care: from theory to practice." Biotechnol J 7, no. 8 (August 2012): 973-979. (Review)

PMID
22180345
Full Text

Snyderman, R. "Introduction of Robert J. Lefkowitz." J Clin Invest 121, no. 10 (October 2011): 4192-4200.

PMID
21965339
Full Text

Dinan, MA, Simmons, LA, and Snyderman, R. "Commentary: Personalized health planning and the Patient Protection and Affordable Care Act: an opportunity for academic medicine to lead health care reform." Acad Med 85, no. 11 (November 2010): 1665-1668.

PMID
20844424
Full Text

Snyderman, R, and Dinan, MA. "Improving health by taking it personally." JAMA 303, no. 4 (January 27, 2010): 363-364.

PMID
20103762
Full Text

Snyderman, R. "Creating meaningful health care reform." J Clin Invest 119, no. 10 (October 2009): 2855-2856.

PMID
20069713
Scholars@Duke

Fineberg, H, and Snyderman, R. "IOM publishes agenda for national summit on integrative medicine." Integrative Medicine 8, no. 1 (2009): 12-13.

Scholars@Duke

Snyderman, R, and Yoediono, Z. "More about prospective health care." Academic Medicine 84, no. 5 (2009): 541--.

Full Text

Snyderman, R, and Yoediono, Z. "In reply." Academic Medicine 84, no. 3 (2009): 290--.

Full Text

Snyderman, R, and Yoediono, Z. "Perspective: Prospective health care and the role of academic medicine: lead, follow, or get out of the way." Acad Med 83, no. 8 (August 2008): 707-714.

PMID
18667879
Full Text

Yoediono, Z, and Snyderman, R. "Proposal for a new health record to support personalized, predictive, preventative and participatory medicine." Personalized Medicine 5, no. 1 (2008): 47-54.

Full Text

Pages